Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145432 | 1.00 | ATM (0.40) | ATMKDM1AHDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL15393959 | 0.85 | SMN1; SMN2 (0.40) | ATMHDAC4SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL461375 | 0.78 | ATM (0.36) | ATMKDM1AHDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL17145405 | 0.78 | ATM (0.36) | ATMKDM1AHDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL818821 | 0.70 | TSHR (0.35) | ATMNPSR1ALDH1A1SLC6A3 | |
| SCHEMBL17145406 | 0.70 | PSEN1 (0.34) | SLC6A3 | |
| SCHEMBL459862 | 0.70 | PSEN1 (0.34) | SLC6A3 | |
| SCHEMBL460975 | 0.67 | SLC6A3 (0.32) | SLC6A3 | |
| SCHEMBL13984796 | 0.65 | TSHR (0.60) | ATMKDM1ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL459785 | 0.65 | SLC6A3 (0.32) | ATMALDH1A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150531-B2 | Tricyclic lactones for treatment of cancer | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2015-10-06 | — | — | US | disclosed |
| EP-2595972-B1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | GLACTONE PHARMA DEV AB (SE) | 2015-08-19 | — | — | EP | disclosed |
| US-20130310451-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2013-11-21 | — | — | US | disclosed |
| EP-2595972-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | Glactone Pharma Development AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010555-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | PARTNERS FÖR UTVECKLINGSINVESTERINGAR INOM LIFE SCIENCES, P.U.L.S. AB (SE) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011864-A1 | BICYCLIC COMPOUNDS AND PROCESS FOR PREPARATION | PARTNERS FÖR UTVECKLINGSINVESTERINGAR INOM LIFE SCIENCES, P.U.L.S. AB (SE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310451-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | STAT3, IL6, STAT6 | ATM 828/4885KDM1A 4543/4885HDAC4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.